Generate Biomedicines, Inc. Common Stock (GENB) — Net Asset Quality Index
Generate Biomedicines, Inc. Common Stock (GENB) has a Net Asset Quality Index of 82.3% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $625.74 Million minus total liabilities of $110.94 Million yields net assets of $514.80 Million. A higher index indicates a stronger, lower-leverage balance sheet. See Generate Biomedicines, Inc. Common Stock liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Generate Biomedicines, Inc. Common Stock Net Asset Quality Index Over Time (2024–2025)
This chart shows how Generate Biomedicines, Inc. Common Stock's Net Asset Quality Index has evolved across 2 annual periods from 2024 to 2025. As of March 2026, the index stands at 82.3%, representing net assets of $514.80 Million against total assets of $625.74 Million USD. Explore Generate Biomedicines, Inc. Common Stock cash flow conversion to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Generate Biomedicines, Inc. Common Stock (2024–2025)
The table below presents the year-by-year Net Asset Quality Index for Generate Biomedicines, Inc. Common Stock from 2024 to 2025, covering 2 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market value of Generate Biomedicines, Inc. Common Stock.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -188.7% | $-623.20 Million | $330.18 Million | $953.38 Million | ▼ -104.8 pp |
| 2024 | -84.0% | $-435.09 Million | $518.26 Million | $953.35 Million | — |